Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00020150 |
Recruitment Status :
Completed
First Posted : January 27, 2003
Last Update Posted : April 29, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase I trial to study the effectiveness of combining temozolomide and O6-benzylguanine in treating children who have solid tumors that have not responded to previous therapy.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Brain and Central Nervous System Tumors Childhood Germ Cell Tumor Extragonadal Germ Cell Tumor Kidney Cancer Liver Cancer Neuroblastoma Ovarian Cancer Sarcoma Unspecified Childhood Solid Tumor, Protocol Specific | Drug: O6-benzylguanine Drug: temozolomide | Phase 1 |
OBJECTIVES:
- Determine the maximum tolerated dose of temozolomide administered with a biologically active dose of O6-benzylguanine (O6-BG) in children with refractory solid tumors.
- Determine the dose-limiting toxicity and the toxicity profile of this combination in these patients.
- Assess the plasma pharmacokinetics of O6-BG and its active metabolite, 8-oxo-O6-BG, in these patients.
- Assess the plasma pharmacokinetics of this combination in these patients.
- Correlate levels of alanine-glyoxylate aminotransferase in peripheral blood mononuclear cells with the degree of hematologic toxicity of this combination in these patients.
OUTLINE: This is a dose-escalation study.
Patients receive O6-benzylguanine (O6-BG) IV over 1 hour followed 30 minutes later by oral temozolomide daily for 5 days. Treatment continues every 28 days for up to 12 courses in the absence of unacceptable toxicity or disease progression.
Sequential dose escalation of O6-BG is followed by sequential dose escalation of temozolomide. Cohorts of 3-6 patients receive escalating doses of O6-BG and temozolomide until the maximum tolerated dose (MTD) of each is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 6 patients experience dose-limiting toxicity.
Quality of life is assessed at baseline and prior to courses 1, 3, 6, 8, and 12.
PROJECTED ACCRUAL: A total of 21-48 patients will be accrued for this study within 1-2 years.
Study Type : | Interventional (Clinical Trial) |
Primary Purpose: | Treatment |
Official Title: | Phase I Trial and Pharmacokinetic Study of Temozolomide and O6-Benzylguanine in Childhood Solid Tumors |
Study Start Date : | June 2000 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | up to 21 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
-
Histologically confirmed solid tumor refractory to standard therapy and for which no potentially curative therapy exists, including, but not limited to:
- Rhabdomyosarcoma and other soft tissue sarcomas
- Ewing's family of tumors
- Osteosarcoma
- Neuroblastoma
- Wilms' tumor
- Hepatic tumors
- Germ cell tumors
- Primary brain tumor
- Histological confirmation may be waived for brainstem or optic gliomas
- Measurable or evaluable disease
- Evidence of progressive disease on prior chemotherapy or radiotherapy or persistent disease after prior surgery
PATIENT CHARACTERISTICS:
Age:
- 21 and under
Performance status:
- ECOG 0-2
Life expectancy:
- At least 8 weeks
Hematopoietic:
- Absolute granulocyte count greater than 1,500/mm^3
- Hemoglobin greater than 8 g/dL
- Platelet count greater than 100,000/mm^3
Hepatic:
- Bilirubin normal
- SGPT less than 2 times upper limit of normal
- No significant hepatic dysfunction
Renal:
- Creatinine normal OR
- Creatinine clearance at least 60 mL/min
Cardiovascular:
- No significant cardiac dysfunction
Pulmonary:
- No significant pulmonary dysfunction
Other:
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- Able to swallow capsules
- No significant unrelated systemic illness that would preclude study (e.g., serious infections or organ dysfunction)
- No prior hypersensitivity to dacarbazine, temozolomide, or polyethylene glycol
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- At least 1 week since prior colony-stimulating factors (e.g., filgrastim [G- CSF], sargramostim [GM-CSF], or epoetin alfa)
- At least 4 months since prior myeloablative therapy requiring bone marrow or stem cell transplantation
- No concurrent anticancer immunotherapy
Chemotherapy:
- See Disease Characteristics
- At least 3 weeks since prior chemotherapy (4 weeks for nitrosoureas) and recovered
- Prior temozolomide allowed provided not administered within past 3 months, no severe toxicities experienced during prior course, and not given in combination with other agents designed to inactivate alanine-glyoxylate aminotransferase
- No other concurrent investigational or standard anticancer chemotherapy
Endocrine therapy:
- Concurrent corticosteroids for control of brain tumor-associated edema allowed provided on stable or decreasing dose for at least 1 week prior to study
Radiotherapy:
- See Disease Characteristics
- At least 4 weeks since prior limited-field radiotherapy
- At least 4 months since prior craniospinal irradiation, total body irradiation, or radiotherapy to more than half of the pelvis
- Recovered from prior radiotherapy
- No concurrent anticancer radiotherapy
Surgery:
- See Disease Characteristics
Other:
- At least 4 weeks since other prior investigational therapy and recovered
- No other concurrent anticancer investigational agents

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00020150
United States, Maryland | |
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support | |
Bethesda, Maryland, United States, 20892-1182 |
Study Chair: | Katherine Warren, MD | National Cancer Institute (NCI) |
Publications of Results:
ClinicalTrials.gov Identifier: | NCT00020150 History of Changes |
Obsolete Identifiers: | NCT00005019 |
Other Study ID Numbers: |
CDR0000067880 NCI-00-C-0105I NCI-237 |
First Posted: | January 27, 2003 Key Record Dates |
Last Update Posted: | April 29, 2015 |
Last Verified: | August 2004 |
recurrent childhood rhabdomyosarcoma childhood craniopharyngioma recurrent childhood brain tumor recurrent neuroblastoma recurrent childhood liver cancer recurrent Wilms tumor and other childhood kidney tumors childhood central nervous system germ cell tumor recurrent osteosarcoma unspecified childhood solid tumor, protocol specific childhood germ cell tumor recurrent childhood soft tissue sarcoma childhood oligodendroglioma childhood choroid plexus tumor childhood grade I meningioma |
childhood grade II meningioma childhood grade III meningioma recurrent childhood cerebellar astrocytoma recurrent childhood cerebral astrocytoma recurrent childhood medulloblastoma recurrent childhood visual pathway and hypothalamic glioma previously treated childhood rhabdomyosarcoma recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor recurrent childhood ependymoma childhood teratoma childhood malignant testicular germ cell tumor childhood extragonadal germ cell tumor childhood malignant ovarian germ cell tumor recurrent childhood malignant germ cell tumor |
Sarcoma Neuroblastoma Liver Neoplasms Neoplasms, Germ Cell and Embryonal Nervous System Neoplasms Central Nervous System Neoplasms Neoplasms Neoplasms, Connective and Soft Tissue Neoplasms by Histologic Type Neoplasms by Site Neuroectodermal Tumors, Primitive, Peripheral Neuroectodermal Tumors, Primitive Neoplasms, Neuroepithelial Neuroectodermal Tumors |
Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Digestive System Neoplasms Digestive System Diseases Liver Diseases Nervous System Diseases Temozolomide O(6)-benzylguanine Antineoplastic Agents, Alkylating Alkylating Agents Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Enzyme Inhibitors |